Wesper Journal

This article explores how oral GLP-1 therapy, specifically Eli Lilly’s investigational pill orforglipron, may transform the treatment of obstructive sleep apnea (OSA) by targeting one of its primary root causes: obesity. It highlights clinical evidence from GLP-1 drugs like tirzepatide (Zepbound), which has already gained FDA approval for OSA, and examines how weight loss through these therapies significantly improves apnea severity. The article also outlines why the upcoming oral formulation is a game-changer, increasing accessibility and adherence for patients. With obesity, diabetes, and OSA deeply intertwined, GLP-1 therapy may soon play a central role in holistic sleep medicine.